Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 13/20 | 0.65 |
| ▸ | CES1 | P23141 | 13/20 | 0.65 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4935172 | 0.86 | CES2 (0.68) | CES2CES1LMNAMAPK1KDM4E | |
| SCHEMBL18726183 | 0.85 | CES2 (0.47) | CES2CES1LMNAMAPK1KDM4E | |
| SCHEMBL15287549 | 0.85 | CES2 (0.50) | CES2CES1LMNAMAPK1KDM4E | |
| SCHEMBL27876515 | 0.85 | CES2 (0.48) | CES2CES1LMNAMAPK1KDM4E | |
| SCHEMBL28833093 | 0.82 | CES2 (0.44) | CES2CES1LMNAMAPK1KDM4E | |
| SCHEMBL31188466 | 0.81 | CES2 (0.47) | CES2CES1LMNAMAPK1KDM4E | |
| SCHEMBL650572 | 0.80 | CES2 (0.68) | CES2CES1LMNAMAPK1KDM4E | |
| SCHEMBL30013497 | 0.80 | CES2 (0.68) | CES2CES1LMNAMAPK1KDM4E | |
| SCHEMBL27428737 | 0.77 | CES2 (0.49) | CES2CES1LMNAMAPK1KDM4E | |
| SCHEMBL27913742 | 0.77 | CES2 (0.49) | CES2CES1LMNAMAPK1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2002067304-A1 | A METHOD OF FORMING RESIST PATTERNS IN A SEMICONDUCTOR DEVICE AND A SEMICONDUCTOR WASHING LIQUID USED IN SAID METHOD | HYON MAN-SOK (KR) | 2002-08-29 | — | — | WO | claimed |
| US-11608347-B2 | Octahydropyrido[1,2-alpha]pyrazines as MAGL inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2023-03-21 | — | — | US | disclosed |
| US-20210024546-A1 | OCTAHYDROPYRIDO[1,2-ALPHA]PYRAZINES AS MAGL INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2021-01-28 | — | — | US | disclosed |
| CN-105985354-A | Pyrimidine derivative, cytotoxic agent and pharmaceutical composition and use of pyrimidine derivative | 南京盖特医药技术有限公司 | 2016-10-05 | — | — | CN | disclosed |
| EP-2376475-A1 | 4-AZETIDINYL-1-HETEROARYL-CYCLOHEXANOL ANTAGONISTS OF CCR2 | Janssen Pharmaceutica N.V. (BE) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010068663-A1 | 4-AZETIDINYL-1-HETEROARYL-CYCLOHEXANOL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2010-06-17 | — | — | WO | disclosed |
| US-20100075984-A1 | DICARBONYLIC COMPOUNDS WITH ANTIBACTERIAL ACTIVITY | LABORATORIOS SALVAT, S.A. (ES) | 2010-03-25 | — | — | US | disclosed |
| CN-1117070-C | Aryl or heteroaryl amides of tetrahydronaphthalene, chroman, thiochroman and 1,2,3,4-tetrahydroquinoline carboxylic acids having retinoid-like biological activity | ALLERGAN SALES INC (US) | 2003-08-06 | — | — | CN | disclosed |
| WO-2002067304-A1 | A METHOD OF FORMING RESIST PATTERNS IN A SEMICONDUCTOR DEVICE AND A SEMICONDUCTOR WASHING LIQUID USED IN SAID METHOD | HYON MAN-SOK (KR) | 2002-08-29 | — | — | WO | disclosed |
| US-6307091-B1 | TRIFLUOROMETHYLATING A TRIFLUOROIODOBENZOIC ACID ESTER WITH ADIFLUORO(FLUOROSULFONYL)ACETIC ACID ESTER IN THE PRESENCE OF A COPPER CATALYST IN AN ORGANIC SOLVENT. | UBE INDUSTRIES, LTD. (JP) | 2001-10-23 | — | — | US | disclosed |
| CN-1214675-A | Aryl or heteroaryl amides of tetrahydronaphthalene, chroman, thiochroman and 1,2,3,4-tetrahydroquinoline carboxylic acids having retinoid-like biological activity | VISION PHARM LP (US) | 1999-04-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210024546-A1 | OCTAHYDROPYRIDO[1,2-ALPHA]PYRAZINES AS MAGL INHIBITORS | PYM1, MAG, MAGI3 | CES2 1922/4885CES1 2242/4885LMNA 2143/4885 |
| US-11608347-B2 | Octahydropyrido[1,2-alpha]pyrazines as MAGL inhibitors | PYM1, MAG, MAGI3 | CES2 1922/4885CES1 2242/4885LMNA 2143/4885 |
| US-20100075984-A1 | DICARBONYLIC COMPOUNDS WITH ANTIBACTERIAL ACTIVITY | AHR, DDC, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | CES2 2374/4885CES1 2241/4885LMNA 1869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.